Podocan and Adverse Clinical Outcome in Patients Admitted With Suspected Acute Coronary Syndromes
BackgroundMarkers of bone and extracellular matrix (ECM) remodeling may be associated with adverse outcomes in atherosclerotic cardiovascular disease. Podocan is a newly discovered ECM glycoprotein, previously not studied in a chest pain population. We wanted to study the association between Podocan...
Saved in:
| Main Authors: | Thomas Andersen, Thor Ueland, Pål Aukrust, Dennis W. Nilsen, Heidi Grundt, Harry Staines, Frederic Kontny |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.867944/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Podocan and adverse clinical outcome in patients admitted with suspected acute coronary syndromes
by: Thomas Andersen, et al.
Published: (2025-07-01) -
Procollagen type 1 N-terminal propeptide is associated with adverse outcome in acute chest pain of suspected coronary origin
by: Thomas Andersen, et al.
Published: (2023-09-01) -
Correction: Procollagen type 1 N-terminal propeptide is associated with adverse outcome in acute chest pain of suspected coronary origin
by: Thomas Andersen, et al.
Published: (2025-07-01) -
Markers of T cell activation and exhaustion in plasma are associated with persistent symptoms up to 18 months following mild SARS-CoV-2 infection
by: Thor Ueland, et al.
Published: (2025-05-01) -
Systemic inflammation is an important risk factor and predictor of graft loss and mortality one year after kidney transplantation
by: Torbjørn F. Heldal, et al.
Published: (2025-02-01)